Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Myeloma Testosterone
Myeloma Testosterone
Short, long-term and late stage chemotherapy side-effects can happen to anyone who has undergone chemotherapy and radiation. Anyone. Myeloma testosterone means identifying chemotherapy side effects and manage them through diagnostic testing, nutrition, supplementation, etc.
I was diagnosed with MM in ’94 and underwent an autologous stem cell transplant in ’95. One of the many chemotherapy side-effects of this aggressive, toxic, procedure is decreased testosterone levels. I’ve been undergoing annual blood testing to monitor my testosterone levels.
I used to think that too much testosterone increased my risk of many health problems including heart disease, prostate cancer, stroke, others. It turns out that the opposite is true. Low levels of testosterone in my blood can be a problem for me…
The studies linked and excerpted below cite the health benefits of normal testosterone levels.
About a year ago my free and serum testosterone levels were a bit low so I decided to supplement with a natural testosterone boosting supplement from Life Extension Foundation called Super Miraforte.
- First, testosterone does not increase the risk of heart attack and stroke.
- Second, high levels of circulating testosterone do not increase prostate cancer risk and
- Third, my testosterone levels are on the very bottom of the normal range, so I am supplementing with a natural testosterone supplement-
The ingredients in Super Miraforte, muira puama, nettle and crysin are documented to increase testosterone levels and the benefits of testosterone are well documented to I think it’s important that I spend some time and a little money to get my testosterone levels back in the middle of the normal levels.
I am both a long-term MM survivor and MM cancer coach. For more information about short, long-term and late stage side effects and how to identify and manage them, scroll down the page, post a question and I will reply ASAP.
Thank you,
David Emerson
- MM Survivor
- MM Coach
- Director PeopleBeatingCancer
Recommended Reading:
- Multiple Myeloma Therapies- Integrative, Complementary, Alternative
- Multiple Myeloma Treatment- “Curative” Therapy for is Anything But…
- Multiple Myeloma-Heart Failure from Autologous Stem Cell Transplant
High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study
“We investigated the association of serum levels of testosterone, the principal androgen in circulation, and sex hormone-binding globulin (SHBG) with risk in a case-control study nested in cohorts in Finland, Norway and Sweden of 708 men who were diagnosed with prostate cancer after blood collection and among 2,242 men who were not. In conditional logistic regression analyses, modest but significant decreases in risk were seen for increasing levels of total testosterone down to odds ratio for top vs. bottom quintile of 0.80…”
Study: No Link Between Testosterone, Heart Attack
“WEDNESDAY, July 2, 2014 (HealthDay News) — Although recent research has linked testosterone therapy with a higher risk for heart attack and stroke, a new study involving more than 25,000 older men suggests otherwise.
The study, funded by the U.S. National Institutes of Health, may help ease some fears about testosterone therapy for patients and their families, the study authors said…
The findings, which were published July 2 in the Annals of Pharmacotherapy, found that testosterone therapy was NOT linked with any increased risk for heart attack. In fact, men at greater risk for heart problems who used testosterone actually had a lower rate of heart attacks than similar men who did not receive this treatment, the researchers said.
“This is a rigorous analysis of a large number of patients,” noted Baillargeon. “Our findings did NOT show an increased risk of heart attack associated with testosterone use in older men,” he said…”
These results suggest that testosterone can be viewed as a marker for general health and a predictor for survival in either general male population or stroke survivors…
The Association of Serum Testosterone Levels With Recurrence and Mortality After Acute Ischemic Stroke in Males
“The current study aimed to investigate whether low testosterone predicted the recurrence and clinical outcomes after acute ischemic stroke (AIS) in males.
The cumulative incidence, overall survival, length of hospital stay, and the percentage of previous stroke were compared between subjects with testosterone <440 ng/dl and >440 ng/dl.
The median age was 62 years (range, 35–93 years). The median serum testosterone at admission was 438 [203] ng/dl (range, 44–816 ng/dl); 55 patients (50%) had testosterone <440 ng/dl and were considered as low testosterone.
The median follow-up was 23 months. During the period, 12 recurrences and 10 deaths occurred. The 1-year and 3-year cumulative recurrence rate were 8.3% and 11.9%, respectively; the 1-year and 3-year overall survival were 96.3% and 84.6%, respectively.
The cumulative recurrence rates were similar between the two testosterone groups (log-rank test, p = .88). Low testosterone was associated with poor survival with marginal significance (log-rank test, p = .079). Men with low testosterone had a higher percentage of previous stroke (29.1% versus 12.7%, p = .035).
The mean lengths of hospital stay were similar between the two testosterone groups (16.6 ± 15.8 days versus 14.0 ± 10.6, p = .31). Total testosterone at admission fails to predict stroke recurrence. However, men with low testosterone at admission are more likely to have previous stroke and may have a higher all-cause mortality rate after AIS…
Discussion-
The current study investigated the association of testosterone levels at admission with the clinical outcomes after AIS in males. The study did not observe an association of testosterone with subsequent recurrence after AIS. Low testosterone at admission might predict a worse overall survival.
The cross-sectional analyses revealed that men with low testosterone had a 2.81-fold greater chance of previous stroke, and the association remained significant after adjusting for age…
Multiple comorbidities and chronic disability are highly prevalent in those with previous stroke, and it is known that low testosterone can be a consequence of accumulating disease burden (Corona et al., 2016). It was demonstrated that men with chronic illness have lower serum testosterone levels than healthy men (Wu et al., 2008)…
The current study observed a marginally significant association of testosterone and the overall survival, and the majority of deaths in the current study were not related to cardiovascular or cerebrovascular diseases.
This finding generally confirmed previous studies that low testosterone increases the risk of death due to all cause, cardiovascular disease, and cancer in the general population (Araujo et al., 2011; Corona, Monami, et al., 2010; Corona et al., 2018a; Corona, Rastrelli, et al., 2011; Khaw et al., 2007; Ruige et al., 2011).
These results suggest that testosterone can be viewed as a marker for general health and a predictor for survival in either general male population or stroke survivors…